The South Korean health authority approved listing Takeda Pharmaceuticals’ Alunbrig (brigatinib) for treating anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) as first-line therapy, seven months after the indication expansion.

The Health Insurance Review and Assessment Service (HIRA) recently published a revised notification of drug prescribed and administered to cancer patients, and it is accepting relevant public opinion until Mar. 25. Without much of objection, the revised notification would come in effect from Apr. 1.

The revised version includes details of a NSCLC treatment Alunbrig and its new reimbursement, a combination therapy of Taxotere (docetaxel) fo